Search
Close this search box.

Two Ebola Vaccine Candidates Set to Enter Phase 2 Trials in DRC

Bunia:Geneva: Two experimental vaccines targeting the Bundibugyo Ebola virus are poised to enter phase 2 clinical trials next week in the Democratic Republic of the Congo, as announced by the World Health Organization (WHO).

According to Anadolu Agency – English, the vaccines, developed by Oxford University and the Serum Institute of India (ChAdOx1) and Moderna, received approval last week to progress to the next phase of the Tumani randomized controlled trial.

The trials, set to commence on November 26 or 27 in Bunia, will focus on assessing the vaccines' safety and their ability to elicit an immune response. Successful candidates will proceed to phase 3, which involves evaluating their effectiveness compared to a standard.

The Tumani trial, initiated on October 23, aims to include more vaccine candidates as they become available. Over 140 participants are already enrolled, with expectations for thousands more as testing expands to additional sites and mobile teams are deployed.

WHO Director-General Tedros Adhanom Ghebreyesus emphasized the ongoing progress in vaccine development amid the Ebola outbreak, which has resulted in over 11,300 cases and 5,500 deaths. He noted the challenge of ongoing insecurity, attacks on health workers, and delays in infection identification, which hinder efforts to control the epidemic.